Is there a blood test available to diagnose Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Blood Tests for Parkinson's Disease: Emerging but Not Yet Standard

While several promising blood-based biomarkers for Parkinson's disease are in active research and development, no blood test is currently part of standard clinical diagnostic guidelines, which still rely on clinical assessment and imaging modalities like ioflupane SPECT/CT to differentiate Parkinsonian syndromes. 1

Current Clinical Standard

The ACR Appropriateness Criteria (2020) make no mention of blood testing in the diagnostic workup of Parkinsonian syndromes 1. The guideline-recommended approach uses:

  • Clinical evaluation to identify Parkinsonian features
  • Ioflupane SPECT/CT as the primary diagnostic imaging tool to differentiate true Parkinsonian syndromes (PD, MSA, PSP, CBD) from essential tremor and drug-induced tremor
  • MRI or CT to exclude structural lesions or atrophy patterns suggesting alternative diagnoses

A normal ioflupane SPECT essentially excludes Parkinsonian syndromes 1.

Emerging Blood-Based Biomarkers

Despite the absence of guideline-endorsed blood tests, recent research shows substantial promise:

Alpha-Synuclein Detection (Most Promising)

The most clinically relevant advances involve detecting pathological α-synuclein in blood:

  • Neuron-derived extracellular vesicles: Pathological α-synuclein conformers from neuronal extracellular vesicles can distinguish PD patients from controls with high accuracy 2. These seeding-competent forms can be amplified using seed amplification assays (SAA).

  • Real-time quaking-induced conversion (RT-QuIC): This ultrasensitive technique detects pathogenic α-synuclein in serum, showing promise for clinical translation 3, 4.

Multi-Marker Panels

Several research groups have developed comprehensive biomarker panels:

  • A proteomic blood test achieved 96% AUC with 79% sensitivity and 97% specificity, yielding 99% negative predictive value at 2% disease prevalence 5

  • Autoantibody panels demonstrated 93.1% sensitivity and 100% specificity for differentiating PD from controls 6

  • Combined markers (Parkin, homocysteine, total proteins, urea) achieved 84.1% AUC for PD diagnosis 7

Novel Individual Markers

Recent discoveries include:

  • IGF-1 (risk factor) and C-reactive protein (protective) with genetic evidence linking them to PD 8
  • Parkin levels showing significant abnormalities in PD patients 7
  • Exosomal microRNAs (miR-151a-5p, miR-24, mir-485-5p, mir-331-5p, mir-214) elevated in both serum and CSF 9

Critical Limitations

No single blood-based α-synuclein assay currently meets performance standards required for standalone clinical application 4. Key challenges include:

  • Methodological heterogeneity: Different assays measure different α-synuclein species (total, oligomeric, phosphorylated, seeding-competent)
  • Compartmental variability: Results differ between plasma, erythrocytes, and extracellular vesicles
  • Technical confounders: Hemolysis significantly affects measurements 4
  • Limited validation: Most studies lack large, multi-center, longitudinal cohorts with diverse ethnic populations

Clinical Bottom Line

For current clinical practice, continue using clinical assessment combined with ioflupane SPECT/CT imaging as recommended by guidelines 1. Blood tests remain investigational and should not replace standard diagnostic approaches.

However, if a validated blood test becomes commercially available and FDA-approved, it would likely serve best as:

  • A screening tool in primary care to rule out PD (given high negative predictive values) 5
  • A first-tier test before proceeding to more expensive imaging
  • An adjunct to clinical diagnosis, not a replacement

The field is rapidly evolving, with α-synuclein seed amplification assays showing the most promise for near-term clinical translation 3, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.